Research Studies
Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For more than 50 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting-edge therapy. At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.
Choosing to participate in a study is an important personal decision. Are you interested in participating in a study? Talk with your doctor and family members or friends about deciding to join a study.
Observational Study Protocol – Fabry Disease Registry
Sponsor: Sanofi-Aventis
Indication: Fabry Disease
Principal Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease
Protocol Name: Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease
Sponsor: Sanofi-Aventis
Indication: Fabry Disease
Principal Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
Phase 2 Study of Lorundrostat Alone or in Combination with Dapagliflozin in adults with HTN and CKD with Albuminuria
Protocol Name: Phase 2 Study of Lorundrostat Alone or in Combination with Dapagliflozin in adults with HTN and CKD with Albuminuria
Sponsor: Mineralys
Indication: Chronic Kidney Disease (CKD)
Principal Investigator: Kim Rice, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Protocol Name: A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Sponsor: AMG 20220159 A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Indication: Antineutrophil Cytoplasmic Antibody-Associated (ANCA) Vasculitis (Newly diagnosed or relapse of granulomatosis with polyangiitis or microscopic polyangiitis)
Principal Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal)
Protocol Name: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
Sponsor: River 3 Renal
Indication: Alport Syndrome, Focal segmental glomerulosclerosis (FSGS)
Primary Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus)
Protocol Name: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Sponsor: Amicus
Indication: Fabry Disease
Primary Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)
Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Sponsor: Dimerix B
Indication: FSGS
Primary Investigator: Kim Rice, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (Vertex)
Protocol Name: Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease
Sponsor: Vertex
Indication: APOL1-Mediated Proteinuric Kidney Disease
Primary Investigator: Bernard Fischbach, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (Boehringer Ingelheim)
Protocol Name: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis
Sponsor: Boehringer Ingelheim
Indication: FSGS
Primary Investigator: Anupkumar Shetty, MD
Location: Charlton Office, 2651 Bolton Boone Drive, DeSoto, TX 75115
Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain (Sanofi-Aventis)
Protocol Name: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Adult Participants With Fabry Disease (PERIDOT)
Sponsor: Sanofi-Aventis
Indication: Fabry Disease
Primary Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204